Scripps Research Institute Scientists Create Extremely Potent and Improved New Derivatives of Successful Anticancer Drug LA JOLLA, CA September 16, 2013 Scientists at The Scripps Research Institute (TSRI) have found a way to make dramatic improvements to the cancer cell-killing power of vinblastine, one of the most successful chemotherapy drugs of the past few decades. The team's modified versions of vinblastine showed 10 to 200 times greater potency than the clinical drug. Even more significantly, these new compounds overcome the drug resistance that emerges upon treatment relapse, which renders continued or subsequent vinblastine treatment ineffective in some patients.
The TSRI researchers expect that similar modifications will boost the effectiveness of vincristine, a closely related drug that is commonly used against childhood leukemias and Hodgkin's disease.
These new compounds should improve on what are already superb anticancer drugs, said Dale L. Boger, who is the Richard and Alice Cramer Professor and Chair of the Department of Chemistry at TSRI. Boger and members of his laboratory reported the discovery in a paper recently published online ahead of print by the journal ACS Medicinal Chemistry Letters.
Anticancer Agents
Vinblastine and vincristine are natural products of a pink-flowered herb known as the Madagascar periwinkle. Although the leaves of the plant had been used in traditional medicines for a range of other conditions, from diabetes to hemorrhoids, drug researchers at Eli Lilly found in the 1960s that the two compounds showed excellent potential as anticancer agents.
Both were found to selectively kill cancer cells by a mechanism that many other cancer drugs, including taxol, epothilones, and colchicine, have followed since they bind a cellular protein called tubulin in a way that interferes with the buildup and breakdown of tubulin-containing chains called microtubules structural elements of cells that play a key role in cell division. When the normal dynamics of their microtubules are disrupted, fast-dividing cancer cells stop dividing and die.
Since the 1960s, vinblastine has been used successfully in combination with other chemotherapy drugs against lymphomas as well as testicular, ovarian, breast, bladder and lung cancers. Vincristine is routinely used in combination regimes against childhood acute lymphoblastic leukemia and non-Hodgkin lymphomas. Both compounds are presently isolated from cultivated fields of the plants that make them naturally, but in trace amounts (0.0001% of the dry leaf weight). Since they are plant-derived natural products, they cannot be accessed using existing biotechnology or genetic engineering methods and, prior to the TSRI efforts, they were viewed as far too complex to be prepare by laboratory organic chemistry techniques. The authors developed a remarkable three-step preparation from commercially available chemicals using chemistry that they invented specifically for this purpose.
A significant limitation of vinblastine and vincristine is that, with extended treatment, they may evoke a powerful form of drug resistance. This resistance comes from a doorkeeper-type molecule called P-glycoprotein (Pgp), which transports infiltrating drug molecules out of the cancer cells. As cancer cells evolve to produce more and more Pgp, drugs fail to reach effective concentrations in cells and cancerous growth resumes. For years, medicinal chemists have tried to find modified versions analogues of these drugs that would overcome Pgp-mediated resistance, but without success.
Developing Extraordinary Potency
Last year, however, in a landmark paper in Organic Letters, Boger and his colleagues described a broad new method for modifying organic compounds like vinblastine, and demonstrated the method by making previously inaccessible variants of the drug. Although it is a versatile method, we developed it specifically so that we could start making these vinblastine analogues that couldn't be made before, Boger said.
As his team used the method to make more new vinblastine analogues, the scientists discovered a type of modification to the drug that limits its usual drop in potency against resistant, Pgp-overproducing cancer cells as compared to non-resistant cancer cells. For the new study, the team explored variations of that modification and eventually found several analogues that were as good at killing resistant cells as ordinary vinblastine is at killing non-resistant cancer cells.
These new analogues were also many times more potent than vinblastine against non-resistant cells which are the kinds of cancer cells almost all patients have at diagnosis. The laboratory of a major drug company, Bristol-Myers Squibb, was able to repeat these results in a larger set of clinically important human tumor cell lines, and Boger's team confirmed that the new analogues' greater potency corresponds to their greater ability to bind to tubulin.
The potency of these analogues is extraordinary they show activity down at the 100 picomolar level [100 trillionths of a mole] against some cell lines, said Boger. So we have something here that's really unique, and we discovered it only because of the novel chemistry we developed.
The other contributors to the paper, Potent Vinblastine C20' Ureas Displaying Additionally Improved Activity Against a Vinblastine-Resistant Cancer Cell Line, were the lead author Timothy J. Barker, and Katharine K. Duncan and Katerina Otrubova, all of TSRI at the time of the study.
Funding for the study came in part from the National Institutes of Health (grants CA042056, CA115526, CA165303).
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the worlds largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is in
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
07/10/2026
Dalet, a leading technology and service provider for media-rich organizations, today announced the latest Long-Term Supported (LTS) release of Dalet Flex. Build...
06/09/2026
June 9 2026, 23:00 (PDT) Dolby and MagentaTV Bring Fans Closer to the FIFA Worl...
20/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
20/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
20/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
20/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
20/08/2026
IPC Expands Brazilian Presence with New Channel Partner CCATech
Industry veterans Carlos Abrah o and Bruno Lopes strengthen local support and expand IPCs prese...
20/08/2026
Zixi Enters Mauritius Market Through Strategic Deployment with MTC Jockey Club
Worlds Oldest Horse Racing Club in the Southern Hemisphere Selects Zixis Softwar...
20/08/2026
LA JOLLA, CA-Scripps Research assistant professor Tiantian Liu has received a five-year NIAID DP2 award from the National Institute of Allergy and Infectious Di...
20/08/2026
Audiences reveal appetite for multicultural Australia on-screen 20 August 2026
Dr Georgie McClean, Dr Rebecca Huntley (L-R)
By Dr Georgie McClean and Dr Rebec...
20/08/2026
How Mavis Studio Is Expanding Live Production Teaching at Sussex
Brie Clayton August 19, 2026
0 Comments
Hero image displays a student about to mix be...
20/08/2026
Vertical Unscripted Series Legal Queens Captured with Blackmagic Design
Brie Clayton August 19, 2026
0 Comments
Reality TV veteran Eric Gardner create...
19/08/2026
As the cost of IP nears price parity with traditional SDI, Reynolds argues that ...
19/08/2026
A private 5G bubble was chosen instead of traditional broadcast RF for the race ...
19/08/2026
(L-R) Rafael Manuel and Isabel Sicat attend the Filipi ana premiere during the 2026 Sundance Film Festival at The Ray Theatre on January 23, 2026, in Park Cit...
19/08/2026
Studio owners invited to have their say on rates cuts
The Music Producers Guild (MPG) are inviting UK-based studios to take part in an in-depth survey that ...
19/08/2026
Vintage-inspired desktop interface revealed
Harrison's latest hardware offering sees them head into the world of audio interfaces, delivering a 10-in/12...
19/08/2026
Granular effect remains locked to scale and tempo
Described as your dream granular effect , Minimal Audio's latest creation is capable of turning any s...
19/08/2026
First polyphonic SWAM instrument incoming
Audio Modeling's latest physical-modelling orchestral instrument is just around the corner, and is now availab...
19/08/2026
World Cup Games Generate 84 Billion Minutes Across FOX, Fox Sports 1 and NBCU...
19/08/2026
July brought typical peak-holiday drops in viewership, driven primarily by viewers stepping away from screens and a visible decline in reach across both traditi...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Henry joins BCE as the company accelerates its commercial strategy and expands its international presence across the media, broadcast and technology markets. He...
19/08/2026
iWedia, a leading provider of software solutions for connected TV devices, today announced a major milestone in Android platform optimization with the successfu...
19/08/2026
NTP Technology announces that ST 2110-30 audio-over-IP connectivity with AES67 and RAVENNA capabilities is now available for the brand's world-class audio i...
19/08/2026
Net Insight has been selected to provide its Nimbra platform by the service provider Big Blue Marble, formerly ORS Group, as the core media transport solution f...
19/08/2026
LiveU has supported Coventry City FC and several other top-flight UK football clubs through one of their most demanding live production challenges of the year, ...
19/08/2026
Nature Seekers Documentary Shot with Blackmagic URSA Cine 12K LF
Brie Clayton August 18, 2026
0 Comments
Filming endangered turtles required camera...
19/08/2026
Neyrinck Brings D-Control Consoles Back to Life on Apple Silicon with D-Control ...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
19/08/2026
Riedel Communications today announced that Edith Cowan University (ECU) in Perth, Australia, implemented a comprehensive communications infrastructure that brin...
19/08/2026
QuickLink, a leading provider of award-winning video production and remote guest contribution solutions, will spotlight a major leap forward in remote guest con...
19/08/2026
Integrated platform melds media asset management, playout automation and newsroom workflows
EMAM, PlayBox Neo and SNEWS have officially launched Nuvex, a conne...
19/08/2026
Screen Australia releases the Private Investment Toolkit to strengthen screen in...
19/08/2026
Do Aussies truly value local content? Unpacking Screen Currency 2026 with Deirdr...
19/08/2026
There's an early Christmas gift for Bookish fans, as UKTV confirms the re-commission of the hit U&alibi drama, created by and starring Mark Gatiss. Viewers ...
19/08/2026
Wednesday 19 August 2026
Sky gives sports fans the chance to watch multiple liv...
19/08/2026
On Saturday September 5 Katie Taylor will step into the ring for the fight of her life against Flora Pili in front of 80,000 fans in Croke Park. A legendary fig...
18/08/2026
SportStream 2026, a free three-day virtual event, will take place September 15-17. One registration provides access to all three days of live programming and on...
18/08/2026
BeckTV will introduce BeckFlow to the European market at IBC2026, demonstrated on the Providius stand (10.F53).
BeckFlow is a web-based schematic documentation...
18/08/2026
Boland Communications will introduce a SMPTE ST 2110 input option for its 4K monitors at IBC2026, along with a new 55-inch super-narrow bezel display for video ...
18/08/2026
Dolby Laboratories and the Seattle Seahawks have announced a partnership integrating Dolby OptiView into the Seahawks' live streaming coverage, making the S...
18/08/2026
For BMG Executive Producer of Sports Production, Graham Taylor, producing live s...
18/08/2026
TMRW Sports has appointed Rufus Hack as President of Golf, a newly created role in which he will lead the company's golf businesses including TGL presented ...
Scripps Research Institute Scientists Create Extremely Potent and Improved New Derivatives of Successful Anticancer Drug LA JOLLA, CA September 16, 2013 Scientists at The Scripps Research Institute (TSRI) have found a way to make dramatic improvements to the cancer cell-killing power of vinblastine, one of the most successful chemotherapy drugs of the past few decades. The team's modified versions of vinblastine showed 10 to 200 times greater potency than the clinical drug. Even more significantly, these new compounds overcome the drug resistance that emerges upon treatment relapse, which renders continued or subsequent vinblastine treatment ineffective in some patients.
